



REC'D 14 DEC 2004

WIPO PCT


The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Signed

Dated

15 November 2004

BEST AVAILABLE COPY

Patents Form 1/77



Patents Act 1977
(Rule 16)

The
Patent
Office

27NOV03 E855589-1 D02029
F01/7700 0.00-0327619.3

1/77

Request for grant of a patent

(See the notes on the back of this form. You can also get
an explanatory leaflet from the Patent Office to help
you fill in this form)

The Patent Office
Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference

MAR/KMM/PB60596P

2. Patent application number

27 NOV 2003

(The Patent Office will fill in his part)

0327619.3

3. Full name, address and postcode of the or of
each applicant (underline all surnames)

SmithKline Beecham Corporation
One Franklin Plaza, P.O. Box 7929, Philadelphia,
Pennsylvania 19101, United States of America

Patents ADP number (if you know it) 05949417004

If the applicant is a corporate body, give the
country/state of its incorporation

Pennsylvania, United States of America

4. Title of the invention

New Use

5. Name of your agent (if you have one)

Corporate Intellectual Property

"Address for service" in the United Kingdom
to which all correspondence should be sent
(including the postcode)

GlaxoSmithKline
Corporate Intellectual Property (CN9 25.1)
980 Great West Road
BRENTFORD
Middlesex TW8 9GS

Patents ADP number (if you know it) 07960982003

6. If you are declaring priority from one or more
earlier patent applications, give the country
and the date of filing of the or each of
these earlier applications and (if you know it) the
or each application number

Country Priority application number Date of filing
(if you know it) (day / month / year)

7. If this application is divided or otherwise
derived from an earlier UK application,
give the number and the filing date of
the earlier application

Number of earlier application Date of filing
(day / month / year)

8. Is a statement of inventorship and of right

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form
Description 12 *S*
Claim(s) 1 *S*
Abstract 1 *S*
Drawings 3 *S*

10. If you are also filing any of the following, state how many against each item.

Priority Documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination
(*Patents Form 10/77*)

Any other documents
(please specify)

11.

We request the grant of a patent on the basis of this application

Signature *Michael Reed* Date 27-Nov-03
M A Reed

12. Name and daytime telephone number of person to contact in the United Kingdom

M A Reed 020 80474455

Warning

After an application for a Patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission unless an application has been filed at least six weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes


- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be

NOVEL USE

This invention relates to a novel use of (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, in particular its use in the treatment of anxiety disorders and
5 in the treatment of mixed anxiety-depressive disorder.

Background of the Invention


Bupropion hydrochloride, (\pm)-1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)-amino]-1-propanone hydrochloride, is the active ingredient of Wellbutrin® which is marketed in the United States for the treatment of depression. It is also the active ingredient of Zyban® which is marketed in the United States as an aid to smoking cessation. Bupropion is a relatively weak inhibitor of the neuronal uptake of noradrenaline (NA), serotonin and dopamine (DA), and does not inhibit monoamine oxidase. While the mechanism of action of bupropion, as with other antidepressants, is unknown, it is presumed that this action is mediated by noradrenergic and/or dopaminergic mechanisms. Available evidence suggests that Wellbutrin® is a selective inhibitor of noradrenaline (NA) at doses that are predictive of antidepressant activity in animal models. See Ascher, J.A., et al., Bupropion: A Review of its Mechanism of Antidepressant Activity. *Journal of Clinical Psychiatry*, 56: p. 395-401, 1995.



Bupropion HCl

Bupropion is extensively metabolized in man as well as laboratory animals. Urinary and plasma metabolites include biotransformation products formed via hydroxylation of the tert-butyl group and/or reduction of the carbonyl group of bupropion. Four basic metabolites have been identified. They are the erythro- and threo-amino alcohols of bupropion, the erythro-amino diol of bupropion, and a morpholinol metabolite.
25


The morpholinol metabolite (+/-)-(2R*,3R*)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol is believed to be formed from hydroxylation of the tert-butyl group of bupropion.
30



Morpholinol Metabolite of Bupropion

It was discovered that despite the (-) form of the morpholinol metabolite predominating significantly in human plasma samples, it was the (+) enantiomer, (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholino in which the optimal

5. monoamine reuptake inhibitory activity resides (WO 99/37305), hereinafter referred to as the compound of formula (I):



10 The compound of formula (I) and its salts and solvates have been disclosed as being of use in the treatment of depression (including major depressive disorder (MDD), bipolar depression (type I and II), major (unipolar) depression and depression with atypical features (eg. lethargy, over-eating/obesity, hypersomnia)), attention deficit hyperactivity disorder (ADHD), obesity, migraine, pain (including neuropathic pain, eg. diabetic neuropathy, sciatica, non-specific lower back pain, multiple sclerosis pain, fibromyalgia, HIV-related neuropathy, neuralgia such as as post-herpetic neuralgia and trigeminal neuralgia and pain resulting from physical trauma, amputation, cancer, toxins or chronic inflammatory conditions), sexual dysfunction (including inhibited sexual desire (low libido), inhibited sexual arousal or excitement, orgasm dysfunction, inhibited female orgasm, inhibited male orgasm, hypoactive sexual desire disorder (HSDD), female sexual desire disorder (FSDD) and sexual dysfunction side-effects induced by treatment with antidepressants of the SSRI-class), Parkinson's disease (including relief from the symptoms of Parkinson's disease which include, but are not limited to, locomotor deficits and/or motor disability, including slowly increasing disability in purposeful movement, tremors,

15

20

25

bradykinesia, hyperkinesia (moderate and severe), akinesia, rigidity, disturbance of balance and co-ordination, and a disturbance of posture), Alzheimer's disease, or addiction to cocaine or nicotine-containing (especially tobacco) products (WO 99/37305 and US2003-0064988; both Glaxo Group Limited).

5 US2003-0032643 (Glaxo Group Limited) discloses the use of the compound of formula (I) and its salts and solvates in the treatment of seasonal affective disorder, chronic fatigue, narcolepsy and cognitive impairment.

US2003-0083330 (Glaxo Group Limited) discloses the use of the compound of formula (I) and its salts and solvates in the treatment of addiction to alcohol.

10 WO 00/51546 and WO 01/62257 (both Sepracor Inc.) disclose the use of a bupropion metabolite in the treatment of a disorder that is ameliorated by the inhibition of neuronal monoamine reuptake, sexual dysfunction (including erectile dysfunction), an affective disorder (including depression, anxiety disorders, attention deficit hyperactivity disorder, bipolar and manic conditions, sexual dysfunction, 15 psycho-sexual dysfunction, bulimia, obesity or weight gain, narcolepsy, chronic fatigue syndrome, seasonal affective disorder, premenstrual syndrome, and substance addiction or abuse), nicotine addiction, a cerebral function disorder (including senile dementia, Alzheimer's type dementia, memory loss, amnesia/amnestic syndrome, epilepsy, disturbances or consciousness, coma, 20 lowering of attention, speech disorders, Parkinson's disease, Lennox syndrome, autistic disorder, autism, hyperkinetic syndrome, schizophrenia, cerebral infarction, cerebral bleeding, cerebral arteriosclerosis, cerebral venous thrombosis and head injury), epilepsy, smoking cessation and incontinence.

25 **Summary of the Invention**

The present invention provides the use of (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol or a salt or solvate thereof, or pharmaceutical compositions thereof, in the manufacture of a medicament for the treatment of anxiety disorders.

30 A further aspect of the invention provides the use of (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol or a salt or solvate thereof, or pharmaceutical compositions thereof, in the manufacture of a medicament for the treatment of mixed anxiety-depressive disorder.

35 A further aspect of the invention provides a method of treating anxiety disorders in a mammalian (human or animal) subject comprising the administration to said subject of an effective amount of (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol or a salt or solvate thereof, or pharmaceutical compositions thereof.

40 A further aspect of the invention provides a method of treating mixed anxiety-depressive disorder in a mammalian (human or animal) subject comprising the administration to said subject of an effective amount of (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol or a salt or solvate thereof, or pharmaceutical compositions thereof.

A further aspect of the present invention provides the use of optically or enantiomerically pure (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol or a salt or solvate thereof or pharmaceutical compositions thereof in the manufacture of a medicament for the treatment of anxiety disorders.

A further aspect of the present invention provides the use of optically or enantiomerically pure (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol or a salt or solvate thereof or pharmaceutical compositions thereof in the manufacture of a medicament for the treatment of mixed anxiety-depressive disorder.

A further aspect of the invention provides a method of treating anxiety disorders in a mammalian (human or animal) subject comprising the administration to said subject of an effective amount of optically or enantiomerically pure (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol or a salt or solvate thereof, or pharmaceutical compositions thereof.

A further aspect of the invention provides a method of treating mixed anxiety-depressive disorder in a mammalian (human or animal) subject comprising the administration to said subject of an effective amount of optically or enantiomerically pure (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol or a salt or solvate thereof, or pharmaceutical compositions thereof.

Detailed Description of the Invention

It will be appreciated that references herein to "treatment" extend to prophylaxis, prevention of recurrence and suppression or amelioration of symptoms (whether mild, moderate or severe) as well as the treatment of established conditions.

As used herein, the term "treatment of anxiety disorders" includes the treatment of generalised anxiety disorders, panic disorder with agoraphobia, panic disorder without agoraphobia, agoraphobia without a history of panic disorder, phobic disorders including social phobias (for example, social anxiety disorders) and specific phobias (also known as simple phobias), obsessive-compulsive disorder, stress disorders (including acute stress disorders and post-traumatic stress disorders), separation anxiety, adjustment disorders with anxious features, anxiety disorders due to a general medical condition, and anxiety disorders due to substance abuse.

Preferred is the treatment of generalised anxiety disorders, panic disorder (with or without agoraphobia), social phobias (for example social anxiety disorders), or stress disorders (including acute stress disorders and post-traumatic stress disorders). Most preferred is the treatment of generalised anxiety disorders (GAD), panic disorder, social anxiety disorders (SAD), or post traumatic stress disorders (PTSD). Of particular note in the context of the present invention is the treatment of generalised anxiety disorders (GAD), or the treatment of social anxiety disorders (SAD).

As used herein, the term "treatment of mixed anxiety-depressive disorder"

refers to the treatment of such a disorder as defined in the appendix of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, 1994 (DSM-IV). The diagnostic criteria for this disorder generally include the presence of persistent or recurrent dysphoric mood lasting for ≥ 4 weeks and accompanied by ≥ 4 of the following symptoms: concentration or memory difficulties, sleep disturbances, fatigue or low energy, irritability, worry, being easily moved to tears, hypervigilence, anticipating the worst, hopelessness or pessimism about the future, or low self-esteem or feelings of worthlessness. The diagnosis encompasses subjects who do not meet the diagnostic criteria for either a depressive disorder or an anxiety disorder, but display a combination of non-specific anxious and depressive symptoms.

As used herein, "optically or enantiomerically pure" means that the composition contains greater than about 90% of the desired stereoisomer by weight, preferably greater than about 95% of the desired stereoisomer by weight, more preferably greater than about 99% of the desired enantiomer by weight, most preferably greater than 99.5% of the desired enantiomer by weight, said weight percent based upon the total weight of the compound of formula (I).

Preferred salts and solvates for use according to the present invention are pharmaceutically acceptable salts or solvates of the compound of formula (I), particularly those disclosed in WO 99/37305, WO 00/51546 and WO 01/62257. Particularly preferred is (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol hydrochloride.

Anxiolytics in current clinical use include selective serotonin re-uptake inhibitors (SSRIs) and benzodiazepines. There are no compounds approved for the treatment of anxiety disorders that are either noradrenaline or dopamine reuptake inhibitors. The results of the studies below illustrate that the compound of formula (I) has a unique anxiolytic profile. In particular, the acute rat social interaction study indicates a different profile from that of SSRIs, in that there is a lack of anxiogenic activity for the compound of formula (I). The evidence of anxiolytic activity from all three studies described below, together with the absence of anxiogenic activity is a particularly advantageous feature of the compound of formula (I).

Description of the Drawings

Figure 1. Effect of compounds on rat social interaction (Male Sprague Dawley rats, 350-400 g, n = 10-14); chronic test

Figure 2. Effect of compounds on rat social interaction (Male Sprague Dawley rats, 350-400 g, n = 10-14); acute test

Figure 3. Effect of compounds on mice in the light & dark box (CD-1 mice, 25-30g,

n=8-10)

Preparation

The compound of formula (I) or a salt or solvate thereof may be prepared in isolated form, and preferably in an optically or enantiomerically pure form, in accordance with the procedures set forth in WO 99/37305, US2003-0064988, US2003-0032643 and US2003-0027827 (all of Glaxo Group Limited) or WO 00/51546 and WO 01/62257 (both of Sepracor Inc.) the procedures of which are herein incorporated by reference.

10

Dosage and Formulation

The compound of formula (I) or a salt or solvate thereof is administered in isolated form, and is preferably administered in an optically or enantiomerically pure form.

15

The amount of compound of formula (I) or a salt or solvate thereof required to achieve the desired therapeutic effect will, of course depend on a number of factors, for example, the mode of administration and the recipient being treated. In general, the daily dose will be in the range of 0.02 to 5.0 mg/kg. More particular ranges include 0.02 to 2.5 mg/kg, 0.02 to 1.0 mg/kg, 0.1 to 1.5 mg/kg, 0.02 to 0.25 mg/kg, 20 0.02 to 0.15 mg/kg and 0.02 to 0.07 mg/kg given as a single once a day dose or as a single or divided doses throughout the day.

20

The compound of formula (I) or a salt or solvate thereof may be employed in the treatment of anxiety disorders or in the treatment of mixed anxiety-depressive disorder as the compound *per se*, but is preferably presented with one or more pharmaceutically acceptable carriers, diluents or excipients in the form of a pharmaceutical formulation. The carriers, diluents and excipients must, of course, be acceptable in the sense of being compatible with the other ingredients of the formulation and must not be deleterious to the recipient. The carrier may be a solid or a liquid, or both, and is preferably formulated with the agent as a unit-dose formulation, for example, a tablet containing 10, 20, 40, 60 or 80mg of the compound of formula (I).

30

The formulations include those suitable for oral, rectal, topical, buccal (e.g. sub-lingual) and parenteral (e.g. subcutaneous, intramuscular, intradermal or intravenous) administration.

35

Formulations suitable for buccal (sub-lingual) administration include lozenges comprising a compound of formula (I) or a salt or solvate thereof in a flavoured base, usually sucrose and acacia or tragacanth, and pastilles comprising the agent in an inert base such as gelatin and glycerin or sucrose and acacia.

40

Formulations of the present invention suitable for parenteral administration conveniently comprise sterile aqueous preparations of a compound of formula (I) or a salt or solvate thereof, preferably isotonic with the blood of the intended recipient. These preparations are preferably administered intravenously, although

administration may also be effected by means of subcutaneous, intramuscular, or intradermal injection. Such preparations may conveniently be prepared by admixing the agent with water and rendering the resulting solution sterile and isotonic with the blood.

5 Formulations suitable for rectal administration are preferably presented as unit-dose suppositories. These may be prepared by admixing a compound of formula (I) or a salt or solvate thereof with one or more conventional solid carriers, for example, cocoa butter, and then shaping the resulting mixture.

10 Formulations suitable for topical application to the skin preferably take the form of an ointment, cream, lotion, paste, gel, spray, transdermal patch, aerosol, or oil. Carriers which may be used include vaseline, lanolin, polyethylene glycols, alcohols, and combinations of two or more thereof.

15 It should be understood that in addition to the ingredients particularly mentioned above, the formulations may include other agents conventional in the art having regard to the type of formulation in question.

Biological Data

In vitro Synaptosomal Uptake

20 *In vitro* uptake was determined, as reported previously, using synaptosomes prepared from rat caudoputamen (for dopamine uptake) and hypothalamus (for NA and serotonin uptake) using [³H]-dopamine, [³H]-NA and [³H]-serotonin as transport substrates, respectively. See Eckhardt, S.B., R.A. Maxwell, and R.M. Ferris, A Structure-Activity Study of the Transport Sites for the Hypothalamic and Striatal Catecholamine Uptake Systems. Similarities and differences. Molecular Pharmacology, 21: p. 374-9, 1982.

25 Synaptosomes for use in obtaining *in vitro* uptake data were prepared from hypothalamus or striatum by gently homogenizing the tissue in a 0.3 M sucrose/25 mM Tris pH 7.4 buffer containing iproniazid phosphate to inhibit monoamine oxidase. The homogenate was centrifuged at 1100 x g at 4°C for 10 min and the supernatant 30 was used for uptake studies. The supernatant (~ 1 mg tissue protein) was incubated with Km concentrations of [³H]-noradrenaline, [³H]-dopamine or [³H]-serotonin at 37°C for 5 minutes in Modified Krebs-Henseleit buffer (118 mM NaCl, 5 mM KCl, 25 mM NaHCO₃, 1.2 mM NaH₂PO₄, 1.2 mM MgSO₄, 11 mM Dextrose, 2.5 mM CaCl₂) in the absence and presence of drug. Under these conditions uptake was linear with respect to both for substrate and tissue (with <5% total substrate transported). Non-specific uptake was defined as uptake at 0°C. [³H]-substrate, which had been transported into synaptosomes, was separated from free [³H]-substrate by filtration

over GF/B filters and washing with cold Krebs-Henseleit buffer. The filters were counted for tritium in a liquid scintillation spectrometer.

The data for *in vitro* synaptosomal uptake are presented below as Table 1. The compound of formula (I), inhibited noradrenaline (NA) uptake with an IC₅₀ of 1.1
5 μM. On dopamine (DA) uptake, the compound of formula (I) had an IC₅₀ of ~10 μM. The compound of formula (I) showed no inhibition of serotonin uptake at 30 μM.

Table 1

Compound	IC ₅₀ NA	IC ₅₀ DA	IC ₅₀ Serotonin
Formula (I)	1.1 ± 0.07	9.3 ± 0.41	>30

Uptake values are means ± SEM of 3 separate experiments. The IC₅₀ values are concentrations (μ M) required for 50% inhibition of uptake.

5

Functional reuptake inhibition on human monoamine transporters

Three separate cell-lines expressing human monoamine transporters for dopamine (hDAT) noradrenaline (hNET) and serotonin (hSERT) were used to measure the functional reuptake inhibiting properties of the compound of formula (I) (as its hydrochloride salt). The following methods were utilised.

Human noradrenaline transporter (hNET): MDCK/hNET (dog kidney) cells (4×10^4 cells/well) expressing the human norepinephrine transporter were plated on 96-well format one day before the assay. When the cells were 80% confluent, cell monolayers were washed and preincubated with test compound and/or vehicle in modified Tris-HEPES buffer pH 7.1 at 25°C for 20 minutes, then 25 nM [³H]Norepinephrine was added to make the total volume to 200 μ l and the cells were further incubated for 10 minutes. Cells in the well were then rinsed twice, solubilized with 1% SDS lysis buffer and the lysate was counted to determine [³H]Norepinephrine uptake. Non-specific signal was determined in the presence of 10 μ M desipramine. Reduction of [³H]Norepinephrine uptake by 50 per cent or more ($\geq 50\%$) relative to vehicle controls indicated significant inhibitory activity.

Human dopamine transporter (hDAT): CHO-K1/hDAT cells (8×10^4 cells/well) expressing the human dopamine transporter (hDAT) were plated on 96-well format one day before the assay. Cells were preincubated with test compound and/or vehicle in modified Tris-HEPES buffer pH 7.1 at 25°C for 20 minutes, then 50 nM [³H]Dopamine was added to make the total volume to 200 μ l and further incubated for 10 minutes. Cells in the well were then rinsed twice, solubilized with 1% SDS lysis buffer and the lysate was counted to determine [³H]Dopamine uptake. Non-specific signal was determined in the presence of 10 μ M nomifensine. Reduction of [³H]Dopamine uptake by 50 per cent or more ($\geq 50\%$) relative to vehicle controls indicates significant inhibitory activity.

Human serotonin transporter (hSERT): HEK-293/hSERT cells (5×10^4 cells/tube) expressing the human serotonin transporter (hSERT) were added into the minitube on 96-tube holder prior to assay. Cells were preincubated with test compound or vehicle in modified Tris-HEPES buffer pH 7.1 at 25°C for 20 minutes, then 65 nM [3H]Serotonin was added to make the total volume to 200 μ l and further incubated for 10 minutes. Cells were then washed by filtration through cell harvester four times with PBS buffer containing 0.1% BSA and the GF/B filter was counted to determine [3H]Serotonin uptake. Non-specific signal was determined in the presence of 10 μ M fluoxetine. Reduction of [3H]Serotonin uptake by 50 percent or more ($\geq 50\%$) relative to vehicle-control indicates significant inhibitory activity.

Compounds were screened at 10, 1, 0.1, 0.01 and 0.001 μ M. These same concentrations were concurrently applied to a separate group of untreated cells and evaluated for possible compound-induced cytotoxicity only if significant inhibition of uptake was observed. Radioactivity retained on the filters was determined by scintillation counting overnight using a Packard scintillation counter.

The potencies for monoamine reuptake inhibition for the hydrochloride salt of the compound of formula (I) are expressed in Table 2 below as IC₅₀ (in μ M; mean \pm SEM) following three separate experiments, each performed in duplicate (n=3). The compound demonstrated reuptake inhibition at both hDAT (pIC₅₀=6.36) and hNET (pIC₅₀=6.70) but reuptake inhibition was not observed on hSERT (pIC₅₀ < 5) at the highest concentration tested (10 μ M). No cytotoxicity was observed at any of the concentrations causing reuptake inhibition.

Table 2

Compound	hNET	hDAT	hSERT
Formula (I).HCl	0.20 \pm 0.05 (n=3)	0.44 \pm 0.01 (n=3)	>10 (n=3)

The compound of formula (I) was also tested in well-characterised models of anxiety and was found to be active as follows.

Social interaction test in rats

[*Animal models for predicting clinical efficacy of anxiolytic drugs: social behaviour.*

30 Neuropsychobiology. 13 (1-2) 55-62, 1985]

Male Sprague Dawley rats (350-400 g at day of test, Charles River, Italy) were individually housed for five days before the test session. The 15 minutes social

interaction test was performed between 9:00 to 14:00. Pairs of rats, weight and treatment matched, were placed in the test arena under high light condition. Active social interaction (sniffing, following, grooming, biting, boxing, crawling over and under) and motor activity, in terms of line crossing were scored by an observer blind to the drug treatment. The animals were treated orally with vehicle (2ml/kg) or with the hydrochloride salt of the compound of formula (I) at 3, 10 and 30mg/kg, 45 minutes prior to the test (acute study), or for 20 days twice a day and with a final treatment given on day 21, the last treatment given 45 minutes before the test (chronic study). An additional group of rats (positive control group) received a single oral dose of chlordiazepoxide (CDP) 4 mg/kg 1 hour before testing.

The results of the chronic study are given below in Table 3 (values given as average \pm s.e.), with the data for social interaction also illustrated in Figure 1.

Table 3

	Vehicle (n=14)	Compound of Formula (I) HCl salt 3 mg/kg (n=14)	Compound of Formula (I) HCl salt 10 mg/kg (n=10)	Compound of Formula (I) HCl salt 30 mg/kg (n=14)	CDP 4mg/kg (n=14)
Time spent in active social interaction	81.2 \pm 5.6 s	114.0 \pm 11.5 s * 40.4%	126.4 \pm 13.8 s * 55.7%	97.6 \pm 8.7 s 20.2%	124.4 \pm 10.7 s ** 53.2%
Number of line crossings	603.7 \pm 17.6	587.0 \pm 29.1	571.0 \pm 44.1	476.2 \pm 42.6 **	560.1 \pm 29.6

15

* p<0.05 ** p<0.01; ANOVA, Dunnett's test

The hydrochloride salt of the compound of formula (I) was able to induce an anxiolytic-like effect in this test at 3 and 10 mg/kg without any significant effects on locomotor activity; at 30 mg/kg a significant reduction in locomotor activity compared to vehicle treated animals was observed, which may explain the lack of effect on social interaction at this dose.

The results for social interaction in the acute study are illustrated in Figure 2.

25

Light & Dark box test in mice

[Costall B. Jones BJ. Kelly ME. Naylor RJ. and Tomkins DM.

Exploration of mice in a black and white test box: validation as a model of anxiety.

Pharmacology, Biochemistry & Behavior. 32 (3):777-85, 1989]

The light-dark box test consists of a Perspex box which is divided into two compartments, two-thirds of which is painted white and the remaining third is painted black. Mice are able to move freely between the two compartments using a small gap in the wall separating the two compartments. The floor is marked with lines, which 5 provided an index of motor activity of the animals (number of line crossings). A white light (60W) is placed over the white compartment of the box to provide a brightly-lit area which the animals find aversive. Mice tend to escape from this area preferring to remain in the black area, returning only occasionally to explore the white area. Anxiolytic compounds increase, dose dependently, the time the animals spend in the 10 aversive white area.

CD-1 mice (25-30g, Charles River, Italy) were placed individually into the centre of the white side of the black/white test box for the 5 min test period and the behaviour of the mice was recorded by remote video recording. Behaviour of the mice was assessed subsequently from the tape recordings by an observer who was 15 unaware of the animals' treatment. Different parameters were assessed to estimate both the anxiolytic and the sedative effects of the compound tested. These include the time spent in the white compartment, latency to the initial movement, number of line crossings in the white and the black compartment, number of rearings in the white and the black compartment, and number of transitions between the two 20 compartments.

The animals were orally treated (10 ml/kg) with the hydrochloride salt of the compound of formula (I) at 1, 3 and 10 mg/kg, 30 minutes before test. An additional group of rats (positive control group) received an oral dose of diazepam (DZP) 1 mg/kg 1 hour before testing. The results are given in Figure 3, which demonstrate 25 that the hydrochloride salt of the compound of formula (I) was able to induce an anxiolytic-like effect in this test at 3 mg/kg.

The application of which this description and claims forms part may be used as a basis for priority in respect of any subsequent application. The claims of such 30 subsequent application may be directed to any novel feature or combination of features described herein. They may take the form of product, composition, process or use claims and may include, by way of example and without limitation, the following claims.


Claims

1. Use of (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol or a salt or solvate thereof, or pharmaceutical compositions thereof, in the manufacture of a medicament for the treatment of anxiety disorders.
2. Use of (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol or a salt or solvate thereof, or pharmaceutical compositions thereof, in the manufacture of a medicament for the treatment of mixed anxiety-depressive disorder.
3. Use according to claim 1 or claim 2 wherein said (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol or the salt or solvate thereof is optically or enantiomerically pure.
4. Use according to any one of claims 1 to 3 wherein the salt is (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol hydrochloride.
5. Method of treating anxiety disorders in a mammalian subject comprising the administration to said subject of an effective amount of (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol or a salt or solvate thereof or pharmaceutical compositions thereof.
6. Method of treating mixed anxiety-depressive disorder in a mammalian subject comprising the administration to said subject of an effective amount of (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol or a salt or solvate thereof or pharmaceutical compositions thereof.
7. Method according to claim 5 or claim 6 wherein said (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol or the salt or solvate thereof is optically or enantiomerically pure.
8. Method as claimed in any one of claims 5 to 7 wherein the salt is (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol hydrochloride.

ABSTRACT


NOVEL USE

This invention relates to a novel use of (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol hydrochloride or a salt or solvate thereof, in particular its use in the treatment of anxiety disorders or in the treatment of mixed anxiety-depressive disorder.

Figure 1


2/3

Figure 2



3/3

Figure 3



PCT/EP2004/013499

SA



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.